The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study was conducted to confirm the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy (DP) in patients with advanced gastric cancer. Materials and Methods: Patients with measurable gastric adenocarcinoma received intravenous docetaxel 75 mg/m2 and cisplatin 75 mg/m2 with premedication on day 1, which was repeated every 3 weeks. All patients received DP as a second-line treatment after failing to 5-FU based chemotherapy. Results: 34 patients were enrolled in this study between January 1998 and August 2003. A total of 112 cycles (median 3 cycles) were administered. Responses were evaluable in 30 patients. The objective response rate was 16.7% (95% CI: 3.5~30.3), with a stable disease in 56.7% (95% CI: 40.0~74.4) and a progressive disease in 26.7% (95% CI: 10.9~42.5) of patients, with a median follow up duration of 20 months for all the patients, The median duration of response, time to progression and overall survival were 2.1 months (95% CI: 0.4~3.9), 4.2 months (95% CI: 2.3~6.1) and 6.8 months (95% CI: 1.3~12.3), respectively, with a 1-year survival rate of 32%. The toxicity was evaluated in 30 patients, with neutropenia being most common. Renal impairment was seen in two patients with grade 3 creatinine elevation and liver enzyme elevation in four with grades 3 and 4. Conclusion: Although DP was an active combination regimen, with a tumor control rate of about 73% and with moderate tolerance, adjustment of the administration schedule, with further evaluation of other combination chemotherapies of docetaxel with new agents, other than cisplatin, seem warranted.(Cancer Res Treat. 2004;36:367-371)
Abstract
This study was conducted to confirm the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy (DP) in patients with advanced gastric cancer. Materials and Methods: Patients with measurable gastric adenocarcinoma received intravenous docetaxel 75 mg/m2 and cisplatin 75 mg/m2 with premedication on day 1, which was repeated every 3 weeks. All patients received DP as a second-line treatment after failing to 5-FU based chemotherapy. Results: 34 patients were enrolled in this study between January 1998 and August 2003. A total of 112 cycles (median 3 cycles) were administered. Responses were evaluable in 30 patients. The objective response rate was 16.7% (95% CI: 3.5~30.3), with a stable disease in 56.7% (95% CI: 40.0~74.4) and a progressive disease in 26.7% (95% CI: 10.9~42.5) of patients, with a median follow up duration of 20 months for all the patients, The median duration of response, time to progression and overall survival were 2.1 months (95% CI: 0.4~3.9), 4.2 months (95% CI: 2.3~6.1) and 6.8 months (95% CI: 1.3~12.3), respectively, with a 1-year survival rate of 32%. The toxicity was evaluated in 30 patients, with neutropenia being most common. Renal impairment was seen in two patients with grade 3 creatinine elevation and liver enzyme elevation in four with grades 3 and 4. Conclusion: Although DP was an active combination regimen, with a tumor control rate of about 73% and with moderate tolerance, adjustment of the administration schedule, with further evaluation of other combination chemotherapies of docetaxel with new agents, other than cisplatin, seem warranted.(Cancer Res Treat. 2004;36:367-371)
참고문헌 (24)
- "World Health Report 1998: A Vision for All" (1998), World Health Organization
- "The naturalhistory and results of surgical therapy for carcinoma of thestomach an analysis of 250 cases", pp.143~52 (1961)
- "Randomized comparison between chemotherapyplus best supportive care with best supportive care inadvanced gastric cancer", 8, pp.163~168 (1997)
- "A comparison of three chemotherapeuticregimens in the treatment of advanced pancreatic and gastriccarcinoma", pp.2061~7 (1985)
- "combination chemotherapy for advanced gastric cancer", pp.5 533~6 (1980)
- "The treatment of advanced gastric cancer: in searchof the right combination", 18, pp.2645~2647 (2000)
- "Evaluation of antitumour effectsof docetaxel (Taxotere) on human gastric cancers in vitro andin vivo", 32, pp.226~230 (1996)
- "The taxanes:an update", 355, pp.1176~1178 (2000)
- "Phase II study of docetaxel as salvagechemotherapy in patients with advanced gastric cancer", 35, pp.145~ (1999)
- "Taxotere-cisplatin inadvanced gastric carcinoma (gastric cancer) an active drugcombination", 17, pp.283~ (1998)
- "Docetaxel and cisplatin in patients withadvanced gastric cancer:results of Japanese phase I", II study, 2002, pp.5, 23~26
- "Docetaxel and cisplatin in patients with advanced orrecurrent gastric cancer:a multicenter pahse I", II study, 2002, pp.5, 160~167
- "Paclitaxel and weekly 24-hourinfusion of 5-fluorouracil", folinic acid in advanced gastriccancer, 1997, pp.24, ~
- "Phase II study of a combination of irinotecan and cisplatinagainst metastatic gastric cancer", 17, pp.319~323 (1999)
- "Phase II trial of the combination ofpaclitaxel and 5-fluorouracil in the treatment of advancedgastric cancer: a novel, safe, and effective regimen.", 22, pp.580~586 (1999)
- "A phase II study of paclitaxel folinic acid and cisplatin in patients with advanced gastriccancer", 83, pp.458~462 (2000)
- "Combination chemotherapy with docetaxel andcisplatin for locally advanced and metastatic gastric cancer", 12, pp.47~51 (2001)
- "A phase II study of docetaxel in patientswith paclitaxel-resistant metastatic breast cancer", 16, pp.3362~3368 (1998)
- "Infusional 5-Fluorouracil, leucovorin and docetaxel in advancedgastric cancer", 35, pp.123~129 (2003)
- "Salvage treatment of advanced gastric cancer usingFEP (5-FU, Etoposide, Cisplatin) combination chemotherapy", 34, pp.382~387 (2002)
- "Docetaxel (Taxotere)-cisplatin (TC) an effectivedrug combination in gastric carcinoma.", 11, pp.301~306 (2000), Swiss Group forClinical Cancer Research (SAKK) and the European Instituteof Oncology (EIO)
- "Docetaxel-epirubicine as secondlinetreatment for patients with advanced gastric cancer", 18, pp.1062~ (1999)
- "Docetaxel (taxotere) as salvage chemotherapyin patients with advanced gastric cancer", 11, pp.67~ (2000), A phase II study ofthe Southern Italian Oncology Group (GOIM).
- "Docetaxel administered on a weekly basis forthe metastatic breast cancer", 18, pp.1212~1219 (2000)